Spago Nanomedical in media
-
7 May, 2024
Spagos CEO: Advancing the Tumorad programme comes first – BioStock
-
27 Mar, 2024
Spago Nanomedicals CEO: “huge commercial opportunities are unfolding – BioStock
-
9 Feb, 2024
Springboard forspagos radionuclide cancer therapy – BioStock
-
15 Jan, 2024
Spago’s phase I/IIa cancer trial progressing steadily – BioStock
-
20 Dec, 2023
Positive data in Spago’s phase IIa endometriosis trial – BioStock
-
14 Dec, 2023
First patient dosed in Spago’s phase I/IIa trial – BioStock
-
30 Oct, 2023
Tumorads potential in transforming cancer care – BioStock
-
24 Oct, 2023
Intervju med VD Mats Hansen – Börsvärlden
-
23 Oct, 2023
Spago Nanomedical’s promising cancer therapy approved for phase I/IIa – BioStock
-
29 Jun, 2023
Spago Nanomedical’s SAB on Tumorad’s potential – BioStock